Lawrence Saperstein, MD
Associate Professor of Radiology and Biomedical ImagingDownloadHi-Res Photo
Cards
Appointments
Additional Titles
Chief, Nuclear Medicine
Contact Info
Radiology & Biomedical Imaging
PO Box 208042
New Haven, CT 06520-8042
United States
Appointments
Additional Titles
Chief, Nuclear Medicine
Contact Info
Radiology & Biomedical Imaging
PO Box 208042
New Haven, CT 06520-8042
United States
Appointments
Additional Titles
Chief, Nuclear Medicine
Contact Info
Radiology & Biomedical Imaging
PO Box 208042
New Haven, CT 06520-8042
United States
About
Titles
Associate Professor of Radiology and Biomedical Imaging
Chief, Nuclear Medicine
Appointments
Radiology & Biomedical Imaging
Associate Professor on TermPrimary
Other Departments & Organizations
- Center for Gastrointestinal Cancers
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Nuclear Medicine
- Oligometastatic Cancer Program
- Radiology & Biomedical Imaging
- Yale Cancer Center
- Yale Medicine
Education & Training
- Fellowship
- Columbia Presbyterian Medical Center (2001)
- Residency
- Columbia Presbyterian Medical Center (2000)
- Internship
- Stanford University Medical Center (1994)
- MD
- Duke University School of Medicine (1993)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Lawrence Saperstein's published research.
Publications Timeline
A big-picture view of Lawrence Saperstein's research output by year.
MingDe Lin, PhD
Anne Marie Boustani, MD
Chi Liu, PhD
Jeffrey Pollak, MD
Michal Kulon, MD
Ming-Kai Chen, MD, PhD
18Publications
67Citations
Publications
2023
Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.
Pouliot F, Gorin M, Rowe S, Saperstein L, Denes B, DiPippo V, Stambler N, Morris M, Siegel B. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. Journal Of Clinical Oncology 2023, 41: 61-61. DOI: 10.1200/jco.2023.41.6_suppl.61.Peer-Reviewed Original ResearchCitationsConceptsBaseline PSA levelsPET/CTLow PSA levelsPSA levelsTreatment recommendationsDisease managementLow baseline PSA levelsBiochemically recurrent prostate cancerPositive PET/CTBaseline PSA valuePhase 3 studySubset of patientsRecurrent prostate cancerProstate cancer patientsAvailable clinical informationConventional imaging resultsYears of ageDisease management plansManagement QuestionnaireEquivocal imagingEvaluable patientsNegative PETSystemic therapyDisease recurrenceInitial staging
2022
Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.
Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score. Journal Of Clinical Oncology 2022, 40: 5024-5024. DOI: 10.1200/jco.2022.40.16_suppl.5024.Peer-Reviewed Original ResearchCitationsConceptsHigh-risk PCaBaseline PSAGleason scoreVolume of interestAverage SUVProstate-specific membrane antigen (PSMA) PET/CTSpecific Membrane Antigen PET/CTBaseline PSA levelsGS 9PET/CTSUV resultsPelvic lymphadenectomyPSA levelsInitial stagingDisease recurrenceProspective studyBiopsy statusMetastatic PCaRadical prostatectomyCT uptakeClinical trialsProstate cancerLesion locationCentral readersNegative lesionsPiflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.
Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score. Journal Of Clinical Oncology 2022, 40: 35-35. DOI: 10.1200/jco.2022.40.6_suppl.035.Peer-Reviewed Original ResearchAltmetricConceptsHigh-risk PCaBaseline PSAGleason scoreVolume of interestAverage SUVProstate-specific membrane antigen (PSMA) PET/CTSpecific Membrane Antigen PET/CTBaseline PSA levelsGS 9Prostate cancer patientsPET/CTSUV resultsPelvic lymphadenectomyPSA levelsInitial stagingDisease recurrenceProspective studyBiopsy statusCancer patientsMetastatic PCaRadical prostatectomyClinical trialsCT uptakeLesion locationCentral readers
2021
PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients
Liu H, Yousefi H, Mirian N, Lin M, Menard D, Gregory M, Aboian M, Boustani A, Chen M, Saperstein L, Pucar D, Kulon M, Liu C. PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients. IEEE Transactions On Radiation And Plasma Medical Sciences 2021, 6: 766-770. PMID: 37284026, PMCID: PMC10241407, DOI: 10.1109/trpms.2021.3131999.Peer-Reviewed Original ResearchCitationsAltmetricMP11-11 CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL
Carroll P, Probst S, Rowe S, Gorin M, Pienta K, Saperstein L, Pouliot F, Patnaik A, Preston M, Alva A, Stambler N, Siegel B, Morris M. MP11-11 CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL. Journal Of Urology 2021, 206: e181-e182. DOI: 10.1097/ju.0000000000001984.11.Peer-Reviewed Original ResearchPSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 5023-5023. DOI: 10.1200/jco.2021.39.15_suppl.5023.Peer-Reviewed Original ResearchCitationsConceptsF-DCFPyL PET/CTPositive predictive valuePhase 3 studyPET/CTProstate cancerPrimary endpointPSA responseF-DCFPyL PET/CT scansF-fluciclovine PET/CTProspective phase 3 studyCorrelative imaging findingsRecurrent prostate cancerPET/CT accuracyConventional imaging modalitiesClinical trial informationDefinitive therapyLocal therapyBaseline imagingMetastatic lesionsImaging findingsAnatomic lesionsLower PSAF-DCFPyLTreatment responseCT scanA prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: e17003-e17003. DOI: 10.1200/jco.2021.39.15_suppl.e17003.Peer-Reviewed Original ResearchConceptsF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseasePhase 2/3 studyCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging reviewLesion countsA prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: 32-32. DOI: 10.1200/jco.2021.39.6_suppl.32.Peer-Reviewed Original ResearchCitationsConceptsF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyPhase II/III studyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseaseCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceIII studyStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging reviewPSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 33-33. DOI: 10.1200/jco.2021.39.6_suppl.33.Peer-Reviewed Original ResearchConceptsF-DCFPyL PET/CTPositive predictive valuePET/CTProstate cancerPrimary endpointPSA responseF-DCFPyL PET/CT scansF-fluciclovine PET/CTProspective phase 3 studyBiochemically recurrent prostate cancerCorrelative imaging findingsPhase 3 studyPhase III studyRecurrent prostate cancerPET/CT accuracyConventional imaging modalitiesDefinitive therapyIII studyLocal therapyMetastatic lesionsBaseline imagingImaging findingsAnatomic lesionsLower PSAF-DCFPyL
2020
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).
Morris M, Carroll P, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Gorin M, Siegel B. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). Journal Of Clinical Oncology 2020, 38: 5501-5501. DOI: 10.1200/jco.2020.38.15_suppl.5501.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPET/CTProstate cancerPrimary endpointOccult diseaseSystemic therapyLocal therapyClinical managementNovel PET imaging agentBiochemically recurrent prostate cancerDrug-related SAEsEquivocal conventional imagingMetastatic prostate cancerRecurrent prostate cancerMajority of ptsBCR prostate cancerCurrent imaging modalitiesPET imaging agentCommon AEsDefinitive therapySecondary endpointsPSA responseMulticenter studyLower PSAPCa cellsF-DCFPyL
Clinical Care
Overview
Clinical Specialties
Nuclear Medicine
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale Medicine
Board Certifications
Nuclear Medicine
- Certification Organization
- AB of Nuclear Medicine
- Latest Certification Date
- 2013
- Original Certification Date
- 2011
Diagnostic Radiology
- Certification Organization
- AB of Radiology
- Original Certification Date
- 2000
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- January 18, 2021
Radiologists Bring New Molecular Imaging Technology to Yale
- August 22, 2019
Yale Radiologists Advance Prostate Cancer Imaging
- May 09, 2019
2019 Honors & Achievements
- January 22, 2019
Imaging Agent Shows Promise for Better Prostate Cancer Detection
Get In Touch
Contacts
Mailing Address
Radiology & Biomedical Imaging
PO Box 208042
New Haven, CT 06520-8042
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.